RECRUITING · INTERVENTIONAL · TREATMENT study · Glioblastoma · Phase 2 · Enrollment 78 · Sponsor: L. Nicolas Gonzalez Castro, MD, PhD
Official title: A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
Summary: This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)
Conditions: Glioblastoma, Recurrent Glioblastoma
Keywords: Glioblastoma, Recurrent Glioblastoma
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE2
Enrollment: 78 (ESTIMATED)
Status: RECRUITING
Completion: 2027-03-01 (ESTIMATED)